Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

8.860 +0.490 (+5.85%)
Streaming Delayed Price Updated: 10:09 AM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 830,794
Open 9.105
Bid (Size) 8.850 (400)
Ask (Size) 8.870 (1,900)
Prev. Close 8.370
Today's Range 8.710 - 9.240
52wk Range 2.960 - 40.37
Shares Outstanding 45,711,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Kaplan Fox Announces the Lead Plaintiff Deadline of September 28, 2026 in the Securities Class Action Against Capricor Therapeutics, Inc. (NASDAQ: CAPR)
From Kaplan Fox & Kilsheimer, LLP
Via GlobeNewswire
News headline image
3 Small-Cap Biotechs With Binary Catalysts on the Calendar ↗
Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices. 
Via MarketBeat

Performance

YTD
-68.7%
-68.7%
1 Month
+33.2%
+33.2%
3 Month
-66.8%
-66.8%
6 Month
-71.0%
-71.0%
1 Year
+46.7%
+46.7%

More News

Read More
News headline image
Kaplan Fox Class Action Reminder: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Lead Plaintiff Deadline is September 28, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to an Approaching Lead Plaintiff Deadline on September 28, 2026
From Kaplan Fox & Kilsheimer, LLP
Via GlobeNewswire
News headline image
Kaplan Fox Shareholder Alert: Deadline to Lead in the Securities Fraud Lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) is September 28, 2026
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
CAPRICOR DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CAPR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
CAPRICOR THERAPEUTICS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 28, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR
From SkyMedia, LLC
Via GlobeNewswire
News headline image
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Seeking Recovery to Contact the Firm Before September 28, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm Before the Securities Class Action Deadline on September 28, 2026
From Kaplan Fox & Kilsheimer, LLP
Via GlobeNewswire
News headline image
LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation
From The Shareholders Foundation, Inc.
Via Business Wire
News headline image
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Lead Plaintiff Deadline on September 28, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CAPR
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Reminds Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to a Securities Class Action Deadline - Contact the Firm Before September 28, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
CAPRICOR THERAPEUTICS, INC. (CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Seek Leadership in a Securities Fraud Lawsuit by September 28, 2026
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Kaplan Fox Notifies Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the Lead Plaintiff Deadline on September 28, 2026
From Kaplan Fox & Kilsheimer, LLP
Via GlobeNewswire
News headline image
Kaplan Fox & Kilsheimer LLP Reminds Investors of a Securities Class Action Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and Lead Plaintiff Deadline on September 28, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Deadline Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Have Until September 28, 2026 to Seek a Lead Plaintiff Role
Via NewMediaWire
Topics Lawsuit

Frequently Asked Questions

Is Capricor Therapeutics, Inc. - Common Stock publicly traded?
Yes, Capricor Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Capricor Therapeutics, Inc. - Common Stock trade on?
Capricor Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Capricor Therapeutics, Inc. - Common Stock?
The ticker symbol for Capricor Therapeutics, Inc. - Common Stock is CAPR on the Nasdaq Stock Market
What is the current price of Capricor Therapeutics, Inc. - Common Stock?
The current price of Capricor Therapeutics, Inc. - Common Stock is 8.860
When was Capricor Therapeutics, Inc. - Common Stock last traded?
The last trade of Capricor Therapeutics, Inc. - Common Stock was at 09/14/26 10:09 AM ET
What is the market capitalization of Capricor Therapeutics, Inc. - Common Stock?
The market capitalization of Capricor Therapeutics, Inc. - Common Stock is 405.01M
How many shares of Capricor Therapeutics, Inc. - Common Stock are outstanding?
Capricor Therapeutics, Inc. - Common Stock has 405M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.